MUFG Securities EMEA plc Raises Holdings in Eli Lilly and Company $LLY

MUFG Securities EMEA plc boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 39.0% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 32,556 shares of the company’s stock after acquiring an additional 9,139 shares during the quarter. MUFG Securities EMEA plc’s holdings in Eli Lilly and Company were worth $34,987,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Bearing Point Capital LLC increased its holdings in Eli Lilly and Company by 3.9% during the fourth quarter. Bearing Point Capital LLC now owns 2,777 shares of the company’s stock valued at $2,984,000 after buying an additional 103 shares during the period. Texas Yale Capital Corp. increased its holdings in Eli Lilly and Company by 1.0% during the fourth quarter. Texas Yale Capital Corp. now owns 6,020 shares of the company’s stock valued at $6,470,000 after buying an additional 60 shares during the period. Wormser Freres Gestion increased its holdings in Eli Lilly and Company by 39.3% during the fourth quarter. Wormser Freres Gestion now owns 677 shares of the company’s stock valued at $728,000 after buying an additional 191 shares during the period. DT Investment Partners LLC grew its holdings in Eli Lilly and Company by 4.3% in the fourth quarter. DT Investment Partners LLC now owns 1,668 shares of the company’s stock worth $1,793,000 after purchasing an additional 68 shares during the last quarter. Finally, Holderness Investments Co. grew its holdings in Eli Lilly and Company by 40.7% in the fourth quarter. Holderness Investments Co. now owns 1,294 shares of the company’s stock worth $1,390,000 after purchasing an additional 374 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark is restoring coverage for Zepbound and adding Foundayo to drug plans, meaning all three major PBMs now cover Lilly’s full obesity portfolio. That should expand access for millions of patients and strengthen Lilly’s market share versus Novo Nordisk. Article Title
• Positive Sentiment: Reuters also reported that Mounjaro outperformed other GLP-1 drugs in some type 2 diabetes patients, reinforcing Lilly’s competitive edge in the diabetes and obesity markets. Article Title
• Positive Sentiment: Wall Street is also reacting to Lilly’s broader pipeline momentum, including positive Phase 1b data for Verve-102 and progress in olomorasib, which supports the view that Lilly is more than just a weight-loss story. Article Title
• Positive Sentiment: Lilly announced a major push into vaccines, including the planned acquisition of Curevo Vaccine for $1.5 billion and other vaccine-developer deals, signaling a new long-term growth avenue outside cardiometabolic care. Article Title
• Positive Sentiment: Analyst and media coverage has been upbeat, with commentary highlighting Lilly’s “brilliant management,” record valuation, and strong pipeline, which can help sustain momentum in the stock. Article Title

Eli Lilly and Company Trading Down 1.9%

NYSE:LLY opened at $1,105.37 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,149.10. The firm has a fifty day simple moving average of $955.92 and a 200-day simple moving average of $1,009.78. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $1.04 trillion, a P/E ratio of 39.27, a PEG ratio of 1.21 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the firm posted $3.34 earnings per share. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Analyst Ratings Changes

LLY has been the topic of several analyst reports. Guggenheim reaffirmed a “buy” rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Rothschild & Co Redburn lifted their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,344.00 price target on shares of Eli Lilly and Company in a report on Friday, May 1st. BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $1,283.00 price target on shares of Eli Lilly and Company in a report on Friday, May 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,227.00.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.